



Selected to support gastro and immune health for infants and children

During childhood, the gut microbiota is developing and is known to contribute to the child's overall health. *Lactobacillus rhamnosus* is a natural constituent of the early infant microbiota and is one of the most researched lactic acid bacteria in the world. Probi Rhamnosus 6594 has been selected by Probi for its gastro protective and immune regulatory properties for the young.

Proposed positioning

Supports Gastro and Immune health in children
Promotes general health for infants and children

Health benefits

Improves gut microbiota and support general health
Supports the immune defense

Short facts

Strain: *Lactobacillus rhamnosus* DSM 6594

Origin: Human mucosa

Documentation: Preclinical and clinical studies

Recommended daily dose: minimum 10^9 CFU

Safety: QPS status, Safe history of use in commercial food products

Different solutions for different needs – product application ideas

Functional food such as yoghurts or smoothies, infant formula or fruit shots


Consumer healthcare products, powdered sticks, sachets or chewable tablets

Patented and clinically documented by Probi

Probi Rhamnosus 6594 is clinically investigated specially in infants and children, proven safe and shown to increase the total level of lactobacilli.

Results from a pre-clinical study also show that Probi Rhamnosus 6594 exerts anti-microbial activity against a number of pathogenic bacteria (among others, *Listeria*, *E. coli*, *Shigella* and *Enterococcus* species).

Significant increase of *L. rhamnosus* in infants after intake of Probi Rhamnosus 6594



Double-blind, placebo-controlled study on infants age 4 days – 3 months

Probi Rhamnosus 6594 survives in the gastrointestinal tract of children and can thereby regulate the growing child's immune system.

A double-blind, placebo-controlled study proved Probi Rhamnosus 6594 to significantly increase the level of anti-inflammatory signaling molecules.

The Probi Select range consists of carefully selected probiotics, patented and clinically documented by Probi. Designed to bring competitive health benefits to broad target groups thanks to high standards of performance and viability. A selection from where relevant health benefits can be addressed in a variation of attractive consumer products.

Please contact Probi for further information:

Probi AB, Lund, Sweden
Probi USA Inc., Redmond, WA, USA
Probi APAC Ltd, Singapore

probi@probi.se | www.probi.com

